MAPT and Alzheimer disease: For example, the study conducted by Pena-Bautista et al. only recruited healthy people with negative biomarkers of AD (CSF Aβ and CSF tau) in the control group [93], while Giubilei et al. did not exclude people with preclinical AD from the control group [91].